ONC
BeiGene Ltd - ADR

2,032
Mkt Cap
$302.75B
Volume
141,214.00
52W High
$355.30
52W Low
$170.99
PE Ratio
-185.47
ONC Fundamentals
Price
$315.74
Prev Close
$318.59
Open
$317.04
50D MA
$324.71
Beta
0.68
Avg. Volume
336,581.57
EPS (Annual)
-$6.13
P/B
9.28
Rev/Employee
$346,559.28
Loading...
Loading...
News
all
press releases
SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments
Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.
Zacks·6h ago
News Placeholder
More News
News Placeholder
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners The Institute for Follicular...
PR Newswire·12h ago
News Placeholder
BeOne Medicines Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation...
Business Wire·9d ago
News Placeholder
BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for BeOne Medicines Ltd. - Sponsored ADR (ONC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3mo ago
News Placeholder
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?
Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·3mo ago
News Placeholder
BeOne Medicines Ltd. - Sponsored ADR (ONC) Surges 4.0%: Is This an Indication of Further Gains?
BeOne Medicines Ltd. - Sponsored ADR (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·3mo ago
News Placeholder
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.
Stocktwits·6mo ago
News Placeholder
BeiGene to Present at Upcoming Investor Conferences
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside...
Business Wire·8mo ago
News Placeholder
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial...
Business Wire·8mo ago
News Placeholder
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer
Stocktwits·9mo ago

Latest ONC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.